Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of tacrolimus/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation.
Offer K, Kolb M, Jin Z, Bhatia M, Kung AL, George D, Garvin JH, Robinson C, Sosna J, Karamehmet E, Satwani P. Offer K, et al. Among authors: kung al. Biol Blood Marrow Transplant. 2015 Mar;21(3):496-502. doi: 10.1016/j.bbmt.2014.11.679. Epub 2014 Dec 20. Biol Blood Marrow Transplant. 2015. PMID: 25536217 Free article. Clinical Trial.
Acute gastrointestinal graft-vs-host disease is associated with increased enteric bacterial bloodstream infection density in pediatric allogeneic hematopoietic cell transplant recipients.
Levinson A, Pinkney K, Jin Z, Bhatia M, Kung AL, Foca MD, George D, Garvin JH, Sosna J, Karamehmet E, Robinson C, Satwani P. Levinson A, et al. Among authors: kung al. Clin Infect Dis. 2015 Aug 1;61(3):350-7. doi: 10.1093/cid/civ285. Epub 2015 May 5. Clin Infect Dis. 2015. PMID: 25948061
Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation.
Kolb M, Offer K, Jin Z, Kahn J, Bhatia M, Kung AL, Garvin JH, George D, Satwani P. Kolb M, et al. Among authors: kung al. Biol Blood Marrow Transplant. 2016 May;22(5):957-61. doi: 10.1016/j.bbmt.2016.02.005. Epub 2016 Feb 13. Biol Blood Marrow Transplant. 2016. PMID: 26880117 Free PMC article.
Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing Outcomes.
Al Mulla N, Kahn JM, Jin Z, Qureshi M, Karamehmet E, Yoon-Jeong Kim G, Levinson AL, Bhatia M, Garvin JH, George D, Kung AL, Satwani P. Al Mulla N, et al. Among authors: kung al. Biol Blood Marrow Transplant. 2016 Aug;22(8):1525-1530. doi: 10.1016/j.bbmt.2016.05.012. Epub 2016 May 17. Biol Blood Marrow Transplant. 2016. PMID: 27223110 Free PMC article.
Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation.
Rustia E, Violago L, Jin Z, Foca MD, Kahn JM, Arnold S, Sosna J, Bhatia M, Kung AL, George D, Garvin JH, Satwani P. Rustia E, et al. Among authors: kung al. Biol Blood Marrow Transplant. 2016 Sep;22(9):1646-1653. doi: 10.1016/j.bbmt.2016.05.014. Epub 2016 May 29. Biol Blood Marrow Transplant. 2016. PMID: 27252110 Free PMC article.
Bacterial bloodstream infections in pediatric allogeneic hematopoietic stem cell recipients before and after implementation of a central line-associated bloodstream infection protocol: A single-center experience.
Chang AK, Foca MD, Jin Z, Vasudev R, Laird M, Schwartz S, Qureshi M, Kolb M, Levinson A, Bhatia M, Kung A, Garvin J, George D, Della-Latta P, Whittier S, Saiman L, Satwani P. Chang AK, et al. Am J Infect Control. 2016 Dec 1;44(12):1650-1655. doi: 10.1016/j.ajic.2016.04.229. Epub 2016 Jul 1. Am J Infect Control. 2016. PMID: 27378008
Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.
Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL. Oberg JA, et al. Among authors: kung al. Genome Med. 2016 Dec 23;8(1):133. doi: 10.1186/s13073-016-0389-6. Genome Med. 2016. PMID: 28007021 Free PMC article. Clinical Trial.
262 results